Text Size

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

This study has been terminated.
(Insufficient cell mobilization for tandem transplants)
Sponsor:
Collaborator:
AnorMED
Information provided by:
Genzyme
ClinicalTrials.gov Identifier:
NCT00396383
First received: November 2, 2006
Last updated: October 5, 2010
Last verified: October 2010
History of Changes
Results First Received: February 11, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Intervention: Drug: plerixafor

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Study enrollment began in November 2004 and the study was terminated in May 2007. A total of 20 participants were planned for this study, however the study was terminated early because of insufficient mobilization of CD34+ cells after treatment with plerixafor alone for use in tandem transplants.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Participants With Multiple Myeloma (MM) Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.

Participant Flow:   Overall Study
    Participants With Multiple Myeloma (MM)  
STARTED     9  
COMPLETED     6  
NOT COMPLETED     3  
Death                 2  
Lost to Follow-up                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Participants With Multiple Myeloma (MM) Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.

Baseline Measures
    Participants With Multiple Myeloma (MM)  
Number of Participants  
[units: participants]
 		  9  
Age  
[units: years]
Mean ± Standard Deviation 		  62.0  ± 8.0  
Gender  
[units: participants]
 		 
Female     6  
Male     3  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg   [ Time Frame: Day 1 up to day 4 ]
  Show Outcome Measure 1

2.  Primary:   Participant Counts of Summarized Adverse Events (AE) During Treatment   [ Time Frame: 1 month ]
  Show Outcome Measure 2

3.  Secondary:   Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment   [ Time Frame: Approximately 2 months ]
  Show Outcome Measure 3

4.  Secondary:   Number of Transplantations That Achieved Platelet (PLT) Engraftment Grouped by Days to Engraftment   [ Time Frame: Approximately 2 months ]
  Show Outcome Measure 4

5.  Secondary:   Number of Participants With a Durable Graft at 12 Months Post Transplantation   [ Time Frame: Approximately month 13 ]
  Show Outcome Measure 5

6.  Post-Hoc:   Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg   [ Time Frame: Day 1 up to day 4 ]
  Show Outcome Measure 6


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Study had limited enrollment prior to termination.  


Results Point of Contact:  
Name/Title: Genzyme Medical Information
Organization: Genzyme Corporation
phone: 800-745-4447


Publications of Results:
Flomenberg N, Comenzo R, Badel K, Calandra G. Single agent AMD3100 mobilization of peripheral blood progenitor cells for autologous transplantation in patients with multiple myeloma (MM) [abstract]. Blood. Nov 16 2006;108(11 Pt 1):965a.


Responsible Party: Medical Monitor, Genzyme Corporation
ClinicalTrials.gov Identifier: NCT00396383     History of Changes
Other Study ID Numbers: AMD3100-2108
Study First Received: November 2, 2006
Results First Received: February 11, 2009
Last Updated: October 5, 2010
Health Authority: United States: Food and Drug Administration